BioCentury
ARTICLE | Product Development

Teva, Celltrion launch fourth U.S. Herceptin biosimilar at modest discount

March 16, 2020 10:16 PM UTC

Teva and Celltrion Monday launched Herzuma trastuzumab-pkrb, a biosimilar version of Genentech’s Herceptin trastuzumab, in the U.S. at a 10% discount to the original product.

The launch price suggests that unlike generic drugs, the launch of multiple biosimilars may not produce price competition. Rather than compete on price, biosimilars manufacturers such as Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) and Celltrion Healthcare Co. Ltd. (KOSDAQ:091990) can instead target different market segments (see “U.S. Biosimilars Glass -- Half Full or Half Empty?”). ...